logo

For the Inventor, By the Inventor

Basel, Switzerland

Nbe-Therapeutics Ag


USPTO Granted Patents = 16



Forward Citations = 43

Loading Chart...
Loading Chart...

11 inventors (with patents filed for the assignee):

goldMedal Ulf Grawunder (16 out of 23 patents)

silverMedal Roger Renzo Beerli (16 out of 20 patents)

bronzeMedal Lorenz Waldmeier (5 out of 6 patents)

4.  Christoph Rader (2 out of 28 patents)

5.  Haiyong Peng (2 out of 4 patents)

6.  Remy Gebleux (2 out of 2 patents)

7.  Ina Hellmann (2 out of 2 patents)

8.  Rémy Gébleux (1 out of 2 patents)

9.  Chasper Puorger (1 out of 1 patent)

10.  Salvatore Di Girolamo (1 out of 1 patent)

11.  Georg Lipps (1 out of 1 patent)


16 patents:

1. 12533420 - SORTASE F AND ITS USE IN METHODS FOR CONJUGATION (2026-01-27),
2. 12275789 - Human antibodies binding to ROR2 (2025-04-14),
3. 12121527 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2024-10-22),
4. 11986535 - Method of producing an immunoligand/payload conjugate (2024-05-21),
5. 11845793 - Anti-ROR1 antibodies (2023-12-19),
6. 11833120 - Binding protein drug conjugates comprising anthracycline derivatives (2023-12-05),
7. 11447546 - Human antibodies binding to ROR2 (2022-09-20),
8. 11364301 - Method of producing an immunoligand/payload conjugate (2022-06-21),
9. 11242388 - ROR1 antibody compositions and related methods (2022-02-08),
10. 10960083 - Binding protein drug conjugates comprising anthracycline derivatives (2021-03-30),
11. 10864277 - Method of producing an immunoligand/payload conjugate (2020-12-15),
12. 10758556 - Anthracycline-based antibody drug conjugates having high in vivo tolerability (2020-09-01),
13. 10618959 - ROR1 antibody compositions and related methods (2020-04-14),
14. 10517959 - Binding protein drug conjugates comprising anthracycline derivatives (2019-12-31),
15. 10188745 - Binding protein drug conjugates comprising anthracycline derivatives (2019-01-29),
Company Overview
Nbe-Therapeutics AG is a biotechnology company based in Basel, Switzerland, focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. The company specializes in leveraging its proprietary technology platform to create targeted therapies that enhance the efficacy and safety of cancer treatments. Nbe-Therapeutics is dedicated to advancing its research in the field of oncology, aiming to address unmet medical needs through its cutting-edge therapeutic approaches.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

16 Patents

#32 in Basel

#763 in Switzerland

#37,831 in the World

Basel, CH
Basel, Switzerland

Nbe-Therapeutics Ag

Forward Citations = 43

11 inventors:

goldMedal Ulf Grawunder (16 out of 23 patents)

silverMedal Roger Renzo Beerli (16 out of 20 patents)

bronzeMedal Lorenz Waldmeier (5 out of 6 patents)

4.  Christoph Rader (2 out of 28 patents)

5.  Haiyong Peng (2 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nbe-Therapeutics Ag. Retrieved from https://idiyas.com/company/nbe-therapeutics-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…